AAA has made an initial investment of US $450K in Atreus Pharmaceuticals Corporation. Depending on successful completion of several milestones, AAA may invest a total of US $6 million to take a majority participation in this company. This investment shall enable the development of a medical imaging technology involving a human plasma protein called Annexin V.
Atreus Pharmaceuticals is a development-stage, biopharmaceutical company headquartered in Ottawa, Canada, developing in-vivo radiopharmaceutical products suitable for Nuclear Medicine (SPECT) imaging and for PET imaging. Atreus Pharmaceuticals’ product line is based on the Annexin V human protein, which binds to phosphatidylserine, a molecule that only shows up on the surface of dead or dying cells.
The technology has the potential to detect conditions such as rheumatoid arthritis, Crohn’s disease and Alzheimer’s disease at their early stage, and when used with the medical isotope Technetium-99, also has the ability to be used to evaluate the response to treatment for lymphoma and lung cancer.
This agreement and partnership will allow AAA to expand into the North American market.
For more details and highlights please refer to the official press releases and press articles posted in the “press room” section.